Memon et al. showed an association of chronic and upregulated IFN signaling with acquired resistance in tumors from NSCLC patients who developed resistance to PD-1/PD-L1 blocking therapy [39]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.